Drug Profile
Research programme: topical phosphodiesterase 4 inhibitors - Amalyte Pharmaceuticals
Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Amalyte Pharmaceuticals
- Class
- Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Atopic dermatitis; Psoriasis
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for research development in Atopic-dermatitis in USA (Topical)
- 04 Nov 2017 No recent reports of development identified for research development in Psoriasis in USA (Topical)
- 01 Apr 2011 Early research is ongoing in USA